Some Medicare Managed Care Plans Restrict Mammograms

News
Article
OncologyONCOLOGY Vol 13 No 6
Volume 13
Issue 6

Some Medicare managed care organizations (MCOs) are telling beneficiaries that they need to get a referral from one of the plan physicians before they can get a mammogram. But that is not what the law says. A woman can get an annual, routine

Some Medicare managed care organizations (MCOs) are telling beneficiaries that they need to get a referral from one of the plan physicians before they can get a mammogram. But that is not what the law says. A woman can get an annual, routine mammogram without any referral. William Scanlon, director of health financing and public health for the General Accounting Office (GAO), says that a study the GAO just did of 16 MCOs found that five of them erroneously stated the mammogram benefit.

And that wasn’t the only problem the GAO found after it combed through the plan documents and contracts for these MCOs. There were problems with the prescription drug benefit, too. Managed care organizations offer outpatient drugs—which are not available as part of Medicare fee-for-service—as an enticement to get people into managed care plans. Scanlon says that one plan stated in its contract with Medicare that it would pay the first $1,200 a year in name brand prescription expenses for each Medicare beneficiary. However, the literature given to potential members by the MCO stated that only the first $600 in name brand prescription expenses would be covered.

Those revelations came out at hearings held by the Senate Special Committee on Aging. Sen. Charles Grassley (R-Iowa), chairman of the committee, says inaccurate information given to beneficiaries by MCOs leads to appeals when benefit claims are then denied.

Recent Videos
Destigmatizing cancer care for incarcerated patients may help ensure that they feel supported both in their treatment and their humanity.
A lower percentage of patients who were released within 1 year of incarceration received guideline-concurrent care vs incarcerated patients.
A collaboration between the Connecticut Departments of Health and Corrections and the COPPER Center aimed to improve outcomes among incarcerated patients.
Computational models help researchers anticipate how ADCs may behave in later lines of development, while they are still in the early stages.
ADC payloads with high levels of potency can sometimes lead to higher levels of toxicity, which can eliminate the therapeutic window for patients with cancer.
According to Greg Thurber, PhD, target-mediated uptake is the biggest driver of efficacy for antibody-drug conjugates as a cancer treatment.
Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer. Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to expect at the 43rd Annual Chemotherapy Foundation Symposium, such as new chemotherapeutics and targeted therapies.
ADCs demonstrate superior efficacy vs chemotherapy but maintain a similar efficacy profile that requires multidisciplinary collaboration to optimally treat.
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
Related Content